Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: growthvalue who wrote (25841)	9/29/1998 3:12:00 PM
From: roy whitt	Respond to of 32384

Does anybody know what Ligands cut of the pills sales are going to be..... I agree with the other post until' you know what kind of moola the pill will bring in . Its kind of hard to tell if this is a good deal........ but I look at it this way to the more drugs they can get to the market and stop the tremendous cash burn they have I will feel a little bit better..... just my opinion.

To: growthvalue who wrote (25841)	9/29/1998 3:21:00 PM
From: celeryroot.com	Read Replies (1) \| Respond to of 32384

I do. Obviously you don't, your death spiral remark is rather dumb. You obviously didn't do your homework.

To: growthvalue who wrote (25841)	9/29/1998 3:35:00 PM
From: aknahow	Read Replies (2) \| Respond to of 32384

GV, we live in a world of the doable. There is little value in wishing for things that can't be done. A straight debt offering could not be made. Even a straight junk bond or high yield bond can't be issued. Straight debt means it will be paid off, and while projections of future earnings are fine for equity holders I have yet to see a debt issue without projection of ability to finance and repay made on historic, actual, earnings as well as collateral. Biotechs burn cash. As you point out, floorless convertibles are less than desirable. Given the difficulties of obtaining continuous funding I think management deserves some credit for putting this deal together. I do not know if looking at acquisitions of other drugs or mergers will be good for LGND. However, I would rather have management at least consider these uses of capital than not consider them at all. Did it make sense to license ELAN's drug? Don't know but as was pointed out this was a minor part of the deal. It was perhaps something both sides thought helped the deal work and i would have trouble thinking that it was really of critical importance in determining if this financing was a good deal for LGND.